7 days in healthcare (August 8th-14th, 2022)

 

Summary

From the point of view of biomedicine, there seems to be a glimpse of a new drug to prevent the transmission of HIV/AIDS, for which there are problems in obtaining an affordable price. Animal testing is the basis for certain advances in medicine. This can be overcome with certain new discoveries, according to the company Lift Sciences.

Regarding Global Health, two key issues: a new zoonosis (“Langya”) appears in China, as published in the NEJM. In certain developed countries it seems that polio, which was considered eradicated, is making a comeback.

Regarding international health policy, the approval of the Inflation Reduction Act (IRA) of 2022 in the United States, about Climate, Fiscal and Health will have a very important impact. Aside from expanding access to insurance through the Affordable Care Act (Obamacare), surely the most far-reaching impact will be on the pharmaceutical industry. Gradually, Medicare will be able to negotiate the price of medicines with the pharmaceutical industry, something that until now it could not do. This radically changes the business model of the pharmaceutical industry, which was based on two things: the protection of intellectual property through patents; and the existence of free prices with high margins in the United States (the largest pharmaceutical market) and regulated prices and lower margins in the rest of the world. A substantial change that will most likely have a global impact. It may also curb the escalation of health care spending in the United States. We’ll see if this doesn’t upset the fast pace of drug innovation.

If we talk about national health policy (Spain), the good news is that, as in all of Europe, covid continues to decrease in incidence, although it is still a worrying disease, due to the number of hospitalized cases and mortality.

In the field of companies, trials for new covid variants begin by BioNTech and Pfizer. More than 2,300 Spanish pharmacies can now sell through the Glovo platform and soon Uber, although only parapharmacy products, not prescription drugs.

Biomedicine

Global health

International health policy

National health policy

Companies